Abstract: Objective To explore the effect of trimetazidine(TMZ) on the level of cardiac troponin Ic(cTnI) in patients with coronary heart disease after percutaneous coronary intervention(PCI) and investigate the effect of trimetazidine on symptoms of recurrent angina after PCI. Methods A total of 93 patients with unstable angina pectoris admitted for elective PCI were randomly assigned to 2 groups to receive or not an acute loading dose of 60 mg of TMZ prior to the intervention and routine dose of 20 mg Tid after it. The frequency of and the increase in the level of cTnI after successful PCI were measured before and 16~18 h after PCI. Recurrent angina and major adverse cardiac events(MACE, including death, re-infarction and target vessel revascularization) at 9 months after the procedure were also compared. Results Totally 79 patients who were successfully undergoing elective PCI were finally enrolled, 35 were assigned into TMA group and 44 into control group. Post-procedural cTnI levels were significantly reduced in the TMZ group at 16~18 h(P<0.05). The frequency of patients with an increase in cTnI over 2 times the upper limit of the control range(0.05 ng/mL) was significantly decreased in the TMZ group(P<0.05). At 9 months follow-up, symptoms of recurrent angina after PCI were significantly relieved in the TMZ group(P<0.05). Conclusion Trimetazidine can limit the post-PCI cTnI release and relieve the symptoms of recurrent angina after PCI.

Key words: percutaneous coronary intervention, cardiac troponin I, trimetazidine, angina